Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients

Status Not yet recruiting

Clinical Trial Summary

This study evaluates generic emtricitabine(FTC) in Chinese naive children chronic hepatitis B patients. Single group of child patients were enrolled, which include HBeAg positive and negative Chronic hepatitis B(CHB)group.

Clinical Trial Description

Generic emtricitabine(FTC) has been approved for treatment of naive chronic hepatitis B(CHB) patients in China. Yet data are limited for this agent in children paitients. The investigators design this trial to test the effect of FTC in Chinese children CHB which including naive HBeAg positive and Negative CHB patients. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02327676
Study type	Interventional
Source	Asian-Pacific Alliance of Liver Disease, Beijing
Contact	Jun Cheng, M.D.
Phone	+86 10 84322116
Email	jun.cheng.ditan@gmail.com
Status	Not yet recruiting
Phase	Phase 4
Start date	January 2015
Completion date	July 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03272009` - Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects	Phase 1
Recruiting	`NCT01456312` - HBsAg Related Response Guided Therapy	Phase 4
Terminated	`NCT01886300` - An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam	N/A
Completed	`NCT01023230` - A Study to Assess DV-601 in Subjects With Chronic Hepatitis B	Phase 1
Completed	`NCT00962975` - A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies	Phase 1
Terminated	`NCT00460850` - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.	Phase 4
Completed	`NCT00536263` - PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)	Phase 3
Completed	`NCT03681132` - The Norwegian Nucleoside Analogue Stop Study	Phase 4
Active, not recruiting	`NCT05473806` - Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes	Phase 4
Withdrawn	`NCT01179594` - A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.	Phase 4
Recruiting	`NCT05057065` - A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
Completed	`NCT04439539` - A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection	Phase 2
Withdrawn	`NCT03125213` - A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects	Phase 2
Active, not recruiting	`NCT04782375` - Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B	Phase 4
Withdrawn	`NCT05550519` - A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment	Early Phase 1
Completed	`NCT02693652` - A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine	Phase 1/Phase 2
Enrolling by invitation	`NCT04160897` - Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Active, not recruiting	`NCT02588937` - Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients	Phase 4
Completed	`NCT02612506` - Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers	Phase 1
Recruiting	`NCT02327416` - A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)	Phase 3